Isis Pharmaceuticals, Inc. and Thomas, McNerney & Partners, LLC, announced today that Altair Therapeutics Inc., a new venture capital-funded biotechnology company, has been created to focus on the discovery, development and commercialization of Isis' antisense drugs to treat asthma and other respiratory conditions.
read more » Discuss Add this link to... Tell a friendBury Add to:
| Bookmarks
FCC.com is the place for all news and information regarding the Federal Communications Commission. Vote for your favorite stories, or become a member to submit stories.